Skip to main navigation Skip to main content
  • CLCSG
  • E-Submission

CH : Convergence Hepatology

OPEN ACCESS
ABOUT
BROWSE ARTICLES
EDITORIAL POLICY
FOR CONTRIBUTORS

Page Path

  • HOME
  • ABOUT
  • Best practice

Best practice

2025 Best practice

Table of contents

1. Website

The URL of the official journal website is http://clcsg.org/. The Convergence Hepatology website demonstrates that care has been taken to ensure high ethical and professional standards. It does not contain any misleading information, including any attempt to mimic another journal/publisher’s site.

2. Name of Journal

The official journal title is Convergence Hepatology. The journal’s abbreviated title is Converg Hepatol.

3. Peer Review Process

Convergence Hepatology has an online submission and peer review system at http://clcsg.org/.

All papers submitted to Convergence Hepatology are reviewed by the editorial team before being sent out for an external peer review to rule out papers that have low priority, insufficient originality, scientific flaws, or absence of a message of importance to the readers of the Journal. A decision about these papers will usually be made within two or three weeks. The remaining articles are usually sent to two reviewers. It would be very helpful if you could suggest a selection of reviewers and include their contact details.

We may not always use the reviewers you recommend, but suggesting reviewers will make our reviewer database much richer; in the end, everyone will benefit. We reserve the right to return manuscripts in which no reviewers are suggested.

4. Ownership and Management

1) Information about the ownership

This journal is owned by the publisher, The Convergence Liver Cancer Study Group (http://clcsg.org/).

2) Management team of a journal

  • ▪ Journal Manager: Jung Gil Park, Yeungnam University, Korea, Editor-in-Chief of The Convergence Hepatology
  • ▪ Manuscript Editor: Jin Publishing, Korea
  • ▪ Layout Editor: Jin Publishing, Korea

5. Governing Body

The governing body is the journal’s editorial board.

6. Editorial Team and Contact Information

The Editorial team is available from the Editorial Board page at the front part of the journal (https://clcsg.org/).

Contact information

The Convergence Liver Cancer Study Group
5F, Bldg. 2, 130 Dongdeok-ro, Jung-gu, Daegu 41944, Korea
Tel: +82-53-200-2547
E-mail: gsnrs@naver.com

7. Copyright and Licensing

1) Copyright

All published papers become the permanent property of The Convergence Liver Cancer Study Group. Copyrights of all published materials are owned by The Convergence Liver Cancer Study Group. Permission must be obtained from The Convergence Liver Cancer Study Group for any commercial use of materials. Every author should sign the copyright transfer agreement forms (https://clcsg.org/).

2) Licensing

This is an open-access journal distributed under the terms of the Creative Commons Attribution Non-commercial license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited for non-commercial purposes (http://creativecommons.org/licenses/by-nc/4.0/).

8. Author Fees

Neither page charge, article processing fee, nor submission fee will be applied. It is a platinum open access journal.

9. Process for Identification of and Dealing with Allegations of Research Misconduct

The Editorial Board of Convergence Hepatology carefully examines whether all submitted manuscripts abide by the ethical guidelines of ICMJE and COPE. The published articles should include statements of conflict of interest, authors’ contributions, Institutional Review Board, informed consent, and human/animal rights.

When the journal faces suspected cases of research and publication misconduct such as a redundant (duplicate) publication, plagiarism, fabricated data, changes in authorship, undisclosed conflicts of interest, an ethical problem discovered with the submitted manuscript, a reviewer who has appropriated an author’s idea or data, complaints against editors, and other issues, the resolving process will follow the flowchart provided by COPE (https://publicationethics.org/resources/flowcharts/).

10. Research & Publication Ethics

Convergence Hepatology follows the guidelines on good publication practice of COPE and the recommendations of the International Committee of Medical Journal Editors (ICMJE).

11. Publishing Schedule

Convergence Hepatology is published biannually on the last day of March and September in both online and printed versions.

12. Access

Convergence Hepatology is an open-access journal. A free full-text service, in both HTML and PDF, is available immediately upon publication without any embargo period.

13. Archiving

It is accessible without a barrier from the National Library of Korea (http://nl.go.kr/) in the event a journal is no longer published.

14. Revenue Sources

Revenue sources of the Journal were the publisher’s support (The Convergence Liver Cancer Study Group) and advertising rates.

15. Advertising

Convergence Hepatology accepts advertisements. Please contact the editorial office for details.

16. Direct Marketing

Journal propagation has been done through the journal website and the distribution of an introduction pamphlet. Invitations to submit a manuscript are usually focused on the presenters at conferences, seminars, or workshops if the topic is related to the journal’s aims and scope.